Credit Suisse Ag Albireo Pharma, Inc. Transaction History

Credit Suisse Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$18.01 - $23.78 $2,449 - $3,234	-136 Reduced 1.19%	11,280 $243,000
Q3 2022 Nov 10, 2022	BUY	$16.32 - $26.37 $1,321 - $2,135	81 Added 0.71%	11,416 $221,000
Q2 2022 Aug 12, 2022	BUY	$18.54 - $37.29 $9,066 - $18,234	489 Added 4.51%	11,335 $225,000
Q1 2022 May 16, 2022	BUY	$23.94 - $33.74 $17,571 - $24,765	734 Added 7.26%	10,846 $324,000
Q4 2021 Feb 14, 2022	BUY	$21.19 - $31.29 $17,651 - $26,064	833 Added 8.98%	10,112 $235,000
Q3 2021 Nov 12, 2021	BUY	$27.36 - $35.98 $2,161 - $2,842	79 Added 0.86%	9,279 $290,000
Q2 2021 Aug 16, 2021	SELL	$28.9 - $36.87 $81,729 - $104,268	-2,828 Reduced 23.51%	9,200 $324,000
Q1 2021 May 14, 2021	SELL	$32.03 - $42.85 $221,039 - $295,707	-6,901 Reduced 36.46%	12,028 $424,000
Q4 2020 Feb 12, 2021	BUY	$31.56 - $42.16 $597,399 - $798,046	18,929 New	18,929 $711,000
Q2 2018 Aug 14, 2018	SELL	$28.9 - $37.31 $200,537 - $258,894	-6,939 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$26.78 - $39.35 $185,826 - $273,049	6,939 New	6,939 $226,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.